ALSO IN THIS MONTH'S ISSUE
From Academia to Industry – How Biopharma Entrepreneurship Became A Calling
While I knew that I wanted to dedicate my life to developing gene therapies to cure human diseases, I could not have predicted that I would leave academia to become an entrepreneur.
How To Identify Capital To Fund Life Sciences Growth
For life sciences companies, funding needs evolve at every stage of growth — creating both challenges and opportunities. Regardless of the stage, it is fundamental to align your funding strategy with your company’s vision.
Don’t Overlook The Risks Of Innovative Clinical Trials
Advancements in AI and machine learning (ML) for data collection and interpretation could increase the threat of cyber-attacks and malicious hacking of private medical data. As such, sponsors shouldn’t overlook the liability risk of such advancements and the corresponding changes that should be made to business insurance.
Readying For Commercialization
Commercialization planning is particularly important in today’s continuously evolving biopharma marketplace. Not only do you have to manage and allocate capital appropriately but also manage and mitigate the inherent risks in the process — to the extent possible.
BEYOND THE PRINTED PAGE
How We Have Changed For The Better Thanks To COVID-195/17/2021
An interview with Mei Mei Hu, cofounder and CEO of Vaxxinity, provides an example of how COVID-19 and Zoom have enabled the seeing and showing of one another’s humanness.
Communicating Authentically During Times Of Crisis4/19/2021
John Fowler, cofounder and CEO of Kezar Life Sciences, shares “A Letter to Kezar Employees,” a best practice example of a leader communicating authentically and transparently during times of crisis (i.e., the killing of George Floyd).
A Lesson Learned The Hard Way4/18/2021
Neil Kumar, cofounder and CEO of BridgeBio, discusses his rationale behind why employees didn’t have titles during the startup phase.